A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Two Doses of RP-G28 in Subjects With Lactose Intolerance
Phase of Trial: Phase II/III
Latest Information Update: 03 Aug 2017
At a glance
- Drugs RP G28 (Primary)
- Indications Lactose intolerance
- Focus Therapeutic Use
- Sponsors Ritter Pharmaceuticals
- 03 Aug 2017 Further analysis of data from this trial published in a Ritter Pharmaceuticals Media Release.
- 12 Apr 2017 Positive top-line results published in a Ritter Pharmaceuticals media release and full analysis of the data is underway.
- 28 Mar 2017 Results published in a Ritter Pharmaceuticals Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History